Payment overview · 2025
General Payments
$849.83
43 reported records · 18 companies
Healthcare provider profile · identity verified
Vinay K Kumar, MD
Allopathic & Osteopathic Physicians|Internal Medicine · ROCKLEDGE, FL · NPI 1184616849
Verified facts
What the public records show
CMS Open Payments records show Vinay K Kumar, MD received $849.83 in general payments during 2025 across 43 reported records.
Amgen Inc. accounted for 16.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 28 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Mounjaro, Ozempic, Rybelsus, Trelegy Ellipta, Ubrelvy, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 94 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Ubrelvy by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Vraylar by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Prolia by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 125 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 232 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 113 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 232 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 102 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Fiasp as an associated drug or biological on 15 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Fiasp by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 379 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 497 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $136.81 | 16.1% | 9 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $95.40 | 11.2% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $75.97 | 8.9% | 4 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $67.57 | 8.0% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $67.34 | 7.9% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $58.08 | 6.8% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $54.70 | 6.4% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $51.17 | 6.0% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $45.46 | 5.3% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $38.08 | 4.5% | 2 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $24.89 | 2.9% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $24.58 | 2.9% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $23.77 | 2.8% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $20.32 | 2.4% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $18.05 | 2.1% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $15.99 | 1.9% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $15.96 | 1.9% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $15.69 | 1.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $849.83 | 43 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $115.74 | 7 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $97.73 | 6 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $75.97 | 4 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $67.57 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $58.08 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $58.02 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $54.70 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $51.43 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $51.43 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $51.17 | 3 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $45.46 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $38.82 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $38.08 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $35.98 | 2 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $24.89 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $24.58 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $23.77 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $22.10 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $21.10 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $21.07 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $20.80 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $20.32 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $18.05 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $16.58 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $15.99 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $15.96 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $15.91 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $15.69 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 497 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 125 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 232 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 102 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 379 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 32 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 113 | exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 37 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
44 | 16 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
94 | 25 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
125 | 41 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
71 | 25 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
232 | 50 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
12 | 12 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
113 | 30 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
232 | 50 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
102 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
50 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Fiasp open payments reported associated product |
CMS Open Payments — General Payments 15 supporting records · 15 recipient NPIs · example record 1188262936 |
Fiasp · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
379 | 91 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
32 | 12 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
497 | 89 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
27 | 27 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1501 | 406 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 1394 | 148 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1150 | 284 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 1086 | 162 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 1078 | 323 |
| Lisinopril | Lisinopril | 1006 | 282 |
| Amlodipine Besylate | Amlodipine Besylate | 954 | 270 |
| Gabapentin | Gabapentin | 903 | 254 |
| Metformin Hcl | Metformin Hcl | 854 | 273 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 814 | 239 |
| Losartan Potassium | Losartan Potassium | 781 | 214 |
| Omeprazole | Omeprazole | 769 | 253 |
| Oxycodone Hcl | Oxycodone Hcl | 654 | 86 |
| Alprazolam | Alprazolam | 606 | 118 |
| Tamsulosin Hcl | Tamsulosin Hcl | 581 | 165 |
| Metoprolol Succinate | Metoprolol Succinate | 543 | 165 |
| Carvedilol | Carvedilol | 529 | 150 |
| Tramadol Hcl | Tramadol Hcl | 516 | 119 |
| Eliquis | Apixaban | 497 | 89 |
| Trazodone Hcl | Trazodone Hcl | 482 | 155 |
| Metoprolol Tartrate | Metoprolol Tartrate | 477 | 126 |
| Pantoprazole Sodium | Pantoprazole Sodium | 477 | 153 |
| Prednisone | Prednisone | 468 | 282 |
| Lorazepam | Lorazepam | 443 | 91 |
| Quetiapine Fumarate | Quetiapine Fumarate | 442 | 137 |
| Fluticasone Propionate | Fluticasone Propionate | 417 | 151 |
| Hydrochlorothiazide | Hydrochlorothiazide | 416 | 134 |
| Clonazepam | Clonazepam | 412 | 62 |
| Furosemide | Furosemide | 401 | 139 |
| Ozempic | Semaglutide | 379 | 91 |
| Glimepiride | Glimepiride | 370 | 107 |
| Duloxetine Hcl | Duloxetine Hcl | 342 | 109 |
| Potassium Chloride | Potassium Chloride | 336 | 105 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 325 | 101 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 323 | 134 |
| Sertraline Hcl | Sertraline Hcl | 314 | 102 |
| Escitalopram Oxalate | Escitalopram Oxalate | 300 | 108 |
| Zolpidem Tartrate | Zolpidem Tartrate | 300 | 60 |
| Clopidogrel | Clopidogrel Bisulfate | 291 | 90 |
| Pioglitazone Hcl | Pioglitazone Hcl | 284 | 94 |
| Bupropion Xl | Bupropion Hcl | 283 | 101 |
| Simvastatin | Simvastatin | 274 | 83 |
| Montelukast Sodium | Montelukast Sodium | 256 | 79 |
| Jardiance | Empagliflozin | 232 | 50 |
| Azithromycin | Azithromycin | 230 | 181 |
| Tizanidine Hcl | Tizanidine Hcl | 230 | 62 |
| Mirtazapine | Mirtazapine | 228 | 71 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 215 | 73 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 211 | 62 |
| Ondansetron Hcl | Ondansetron Hcl | 204 | 89 |
| Pregabalin | Pregabalin | 201 | 45 |
| Alendronate Sodium | Alendronate Sodium | 191 | 56 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 185 | 155 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 183 | 61 |
| Ibuprofen | Ibuprofen | 181 | 84 |
| Meloxicam | Meloxicam | 181 | 70 |
| Allopurinol | Allopurinol | 179 | 53 |
| Fluoxetine Hcl | Fluoxetine Hcl | 173 | 48 |
| Glipizide | Glipizide | 173 | 49 |
| Diazepam | Diazepam | 172 | 28 |
| Finasteride | Finasteride | 160 | 48 |
| Spironolactone | Spironolactone | 159 | 59 |
| Famotidine | Famotidine | 154 | 47 |
| Buspirone Hcl | Buspirone Hcl | 149 | 42 |
| Atenolol | Atenolol | 148 | 39 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 148 | 52 |
| Xarelto | Rivaroxaban | 148 | 42 |
| Temazepam | Temazepam | 142 | 36 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 141 | 95 |
| Pravastatin Sodium | Pravastatin Sodium | 134 | 39 |
| Ezetimibe | Ezetimibe | 133 | 35 |
| Levetiracetam | Levetiracetam | 132 | 27 |
| Methocarbamol | Methocarbamol | 131 | 53 |
| Diclofenac Sodium | Diclofenac Sodium | 129 | 60 |
| Topiramate | Topiramate | 129 | 28 |
| Farxiga | Dapagliflozin Propanediol | 125 | 41 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 121 | 38 |
| Memantine Hcl | Memantine Hcl | 113 | 27 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 113 | 30 |
| Ropinirole Hcl | Ropinirole Hcl | 112 | 29 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 112 | 78 |
| Citalopram Hbr | Citalopram Hydrobromide | 111 | 42 |
| Entresto | Sacubitril/Valsartan | 110 | 27 |
| Baclofen | Baclofen | 106 | 31 |
| Valsartan | Valsartan | 106 | 32 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 105 | 22 |
| Mounjaro | Tirzepatide | 102 | 19 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 98 | 84 |
| Synthroid | Levothyroxine Sodium | 94 | 25 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 90 | 12 |
| Fluconazole | Fluconazole | 90 | 56 |
| Cefuroxime | Cefuroxime Axetil | 88 | 71 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 85 | 30 |
| Chlorthalidone | Chlorthalidone | 84 | 24 |
| Valacyclovir | Valacyclovir Hcl | 84 | 36 |
| Aripiprazole | Aripiprazole | 83 | 30 |
| Amoxicillin | Amoxicillin | 82 | 62 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 81 | 25 |
| Warfarin Sodium | Warfarin Sodium | 81 | 24 |
| Doxepin Hcl | Doxepin Hcl | 79 | 18 |
| Latanoprost | Latanoprost | 79 | 17 |
| Ondansetron Odt | Ondansetron | 79 | 38 |
| Dicyclomine Hcl | Dicyclomine Hcl | 77 | 22 |
| Novolog Flexpen | Insulin Aspart | 77 | 23 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 77 | 20 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 74 | 23 |
| Nifedipine Er | Nifedipine | 72 | 18 |
| Symbicort | Budesonide/Formoterol Fumarate | 71 | 25 |
| Meclizine Hcl | Meclizine Hcl | 70 | 32 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 69 | 19 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 68 | 27 |
| Lamotrigine | Lamotrigine | 67 | 22 |
| Promethazine Hcl | Promethazine Hcl | 67 | 20 |
| Naproxen | Naproxen | 65 | 27 |
| Celecoxib | Celecoxib | 64 | 24 |
| Ketoconazole | Ketoconazole | 63 | 31 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 62 | 48 |
| Clonidine Hcl | Clonidine Hcl | 62 | 21 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 62 | 42 |
| Benazepril Hcl | Benazepril Hcl | 61 | 16 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 61 | 17 |
| Lidocaine | Lidocaine | 61 | 16 |
| Paroxetine Hcl | Paroxetine Hcl | 60 | 19 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 58 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 57 | 16 |
| Hydralazine Hcl | Hydralazine Hcl | 57 | 26 |
| Cephalexin | Cephalexin | 56 | 49 |
| Lovastatin | Lovastatin | 56 | 17 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 55 | 11 |
| Bupropion Hcl Sr | Bupropion Hcl | 52 | 16 |
| Clobetasol Propionate | Clobetasol Propionate | 52 | 28 |
| Sumatriptan Succinate | Sumatriptan Succinate | 52 | 12 |
| Amiodarone Hcl | Amiodarone Hcl | 51 | 15 |
| Morphine Sulfate Er | Morphine Sulfate | 51 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 51 | 19 |
| Varenicline Tartrate | Varenicline Tartrate | 51 | 21 |
| Trulicity | Dulaglutide | 50 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 49 | 16 |
| Divalproex Sodium | Divalproex Sodium | 48 | 16 |
| Doxycycline Hyclate | Doxycycline Hyclate | 48 | 39 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 48 | 14 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 48 | 39 |
| Acyclovir | Acyclovir | 47 | 15 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 47 | 13 |
| Digoxin | Digoxin | 47 | 16 |
| Sildenafil Citrate | Sildenafil Citrate | 47 | suppressed |
| Lactulose | Lactulose | 45 | 21 |
| Ventolin Hfa | Albuterol Sulfate | 45 | 22 |
| Azelastine Hcl | Azelastine Hcl | 44 | 19 |
| Calcitriol | Calcitriol | 44 | 15 |
| Linzess | Linaclotide | 44 | 16 |
| Breo Ellipta | Fluticasone/Vilanterol | 43 | 13 |
| Estradiol | Estradiol | 43 | 16 |
| Levofloxacin | Levofloxacin | 43 | 36 |
| Methotrexate | Methotrexate Sodium | 43 | 19 |
| Sotalol | Sotalol Hcl | 43 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 42 | 15 |
| Nitroglycerin | Nitroglycerin | 42 | 22 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 41 | 14 |
| Fenofibrate | Fenofibrate | 41 | 12 |
| Glipizide Er | Glipizide | 41 | 12 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 41 | 16 |
| Verapamil Er | Verapamil Hcl | 41 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 40 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 40 | 13 |
| Myrbetriq | Mirabegron | 39 | suppressed |
| Brilinta | Ticagrelor | 38 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 37 | 15 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 37 | 12 |
| Vraylar | Cariprazine Hcl | 37 | suppressed |
| Mupirocin | Mupirocin | 36 | 22 |
| Nystatin | Nystatin | 35 | 17 |
| Scopolamine | Scopolamine | 35 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 35 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 34 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 32 | suppressed |
| Lansoprazole | Lansoprazole | 32 | 16 |
| Rybelsus | Semaglutide | 32 | 12 |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 31 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 31 | suppressed |
| Folic Acid | Folic Acid | 31 | 13 |
| Olanzapine | Olanzapine | 31 | 11 |
| Tresiba Flextouch U-100 | Insulin Degludec | 31 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 30 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 30 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 30 | suppressed |
| Jantoven | Warfarin Sodium | 30 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 30 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 30 | suppressed |
| Clotrimazole | Clotrimazole | 29 | 18 |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 28 | suppressed |
| Methimazole | Methimazole | 28 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 28 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 27 | 12 |
| Paxlovid | Nirmatrelvir/Ritonavir | 27 | 27 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 27 | 15 |
| Enalapril Maleate | Enalapril Maleate | 26 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 26 | suppressed |
| Telmisartan | Telmisartan | 26 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 26 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 25 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 25 | 11 |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 25 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 25 | suppressed |
| Risperidone | Risperidone | 25 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 24 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 24 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 24 | suppressed |
| Januvia | Sitagliptin Phosphate | 23 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 23 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 23 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 23 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 22 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 22 | suppressed |
| Ramipril | Ramipril | 22 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 22 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 22 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 22 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 21 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 21 | suppressed |
| Fentanyl | Fentanyl | 21 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 21 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Torsemide | Torsemide | 21 | suppressed |
| Clozapine | Clozapine | 20 | suppressed |
| Colchicine | Colchicine | 20 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 20 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 20 | 11 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 20 | 12 |
| Lacosamide | Lacosamide | 20 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 20 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 20 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 19 | 11 |
| Bupropion Hcl | Bupropion Hcl | 19 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 19 | suppressed |
| Cyclosporine | Cyclosporine | 19 | suppressed |
| Erythromycin | Erythromycin Base | 19 | 15 |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 19 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 19 | suppressed |
| Irbesartan | Irbesartan | 19 | suppressed |
| Lubiprostone | Lubiprostone | 19 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 19 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 18 | suppressed |
| Metronidazole | Metronidazole | 18 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 18 | suppressed |
| Primidone | Primidone | 18 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 18 | suppressed |
| Ubrelvy | Ubrogepant | 18 | suppressed |
| Amiloride Hcl | Amiloride Hcl | 17 | suppressed |
| Budesonide | Budesonide | 17 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 17 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 17 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 17 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 17 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 17 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 16 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 16 | suppressed |
| Hydrocortisone | Hydrocortisone | 16 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 16 | suppressed |
| Loperamide | Loperamide Hcl | 16 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 16 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 15 | suppressed |
| Carbamazepine | Carbamazepine | 15 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 15 | suppressed |
| Enalapril-Hydrochlorothiazide | Enalapril/Hydrochlorothiazide | 15 | suppressed |
| Eszopiclone | Eszopiclone | 15 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 15 | suppressed |
| Naloxone Hcl | Naloxone Hcl | 15 | 13 |
| Ammonium Lactate | Ammonium Lactate | 14 | suppressed |
| Clonidine | Clonidine | 14 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 14 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 14 | suppressed |
| Haloperidol | Haloperidol | 14 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 14 | suppressed |
| Lisdexamfetamine Dimesylate | Lisdexamfetamine Dimesylate | 14 | suppressed |
| Modafinil | Modafinil | 14 | suppressed |
| Novolin R Flexpen | Insulin Regular, Human | 14 | suppressed |
| Novolog | Insulin Aspart | 14 | suppressed |
| Premarin | Estrogens, Conjugated | 14 | suppressed |
| Vyvanse | Lisdexamfetamine Dimesylate | 14 | suppressed |
| Benzonatate | Benzonatate | 13 | suppressed |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 13 | suppressed |
| Bumetanide | Bumetanide | 13 | suppressed |
| Carbamazepine Er | Carbamazepine | 13 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 13 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 13 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 13 | suppressed |
| Movantik | Naloxegol Oxalate | 13 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 13 | suppressed |
| Oxazepam | Oxazepam | 13 | suppressed |
| Prolia | Denosumab | 13 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 12 | 12 |
| Aripiprazole Odt | Aripiprazole | 12 | suppressed |
| Cefdinir | Cefdinir | 12 | 11 |
| Memantine Hcl Er | Memantine Hcl | 12 | suppressed |
| Phenytoin | Phenytoin | 12 | suppressed |
| Sucralfate | Sucralfate | 12 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 12 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Carisoprodol | Carisoprodol | 11 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 11 | suppressed |
| Desloratadine | Desloratadine | 11 | suppressed |
| Fiasp | Insulin Aspart (Niacinamide) | 11 | suppressed |
| Levemir Flexpen | Insulin Detemir | 11 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 11 | suppressed |
| Proair Respiclick | Albuterol Sulfate | 11 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 11 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 11 | suppressed |
| Zonisamide | Zonisamide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $849.83 · 43 records | Amgen Inc. | AIRSUPRA, BREZTRI, CAPLYTA, ELIQUIS, FANAPT, FARXIGA, FREESTYLE LIBRE 3, GEMTESA, JARDIANCE, KRYSTEXXA, Kerendia, Leqembi, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, QULIPTA, REPATHA, Rybelsus, TRELEGY ELLIPTA, TRINTELLIX, UBRELVY, VOQUEZNA, VRAYLAR, Veozah, XIFAXAN, ZAVZPRET, ZEPBOUND | 20 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error